Researchers have moved closer to a long-standing goal in immunology: a single formulation that can guard against multiple respiratory threats rather than one pathogen at a time. In mouse experiments, a universal nasal spray vaccine protected against multiple viruses, two hard-to-treat bacteria, and even an allergy trigger linked to asthma-like responses. <\/p>\n\n\n\n
The team delivered the candidate intranasally, like a nasal spray, to focus immune defenses where many infections begin: the airways and lungs. The findings appeared in Science<\/em> on February 19, 2026, according to Stanford Medicine\u2019s report. <\/p>\n\n\n\n The researchers tested the vaccine against SARS-CoV-2 and other coronaviruses. After three doses, vaccinated mice showed a sharply lower viral burden in the lungs, and protection that lasted about three months in the reported experiments. <\/p>\n\n\n\n The study also tracked timing. ScienceAlert reported that vaccinated mice mounted a faster adaptive response in the lungs, within 3 days, rather than the up to 2 weeks often seen without prior priming. <\/p>\n\n\n\n Then the surprise: the same approach also helped against bacterial infections, including Staphylococcus aureus and Acinetobacter baumannii, pathogens often associated with hospital-acquired illness and rising concerns about antibiotic resistance. <\/p>\n\n\n\n The team also challenged mice with house dust mites, a common allergen. In those tests, the vaccine reduced asthma-like signals. <\/p>\n\n\n\n A Different Strategy Than Classic \u201cAntigen-Only\u201d Vaccines<\/p>\n\n\n\n Most modern vaccines train the immune system with a recognizable piece of a specific pathogen, so the body prepares targeted antibodies and memory cells for that antigen. That strategy saves lives, but it can struggle when viruses mutate and change surface features, which helps explain why flu shots and COVID-19 boosters often need updates. <\/p>\n\n\n\n This project took another route. Stanford Medicine described the approach as one that pushes the lungs\u2019 defenses into a longer-lasting, ready state, rather than focusing only on a single pathogen \u201clook.\u201d<\/p>\n\n\n\n The formulation highlighted in public coverage is named GLA-3M-052-LS+OVA. ScienceAlert described it as a nasal-delivered vaccine tested in three doses. <\/p>\n\n\n\n Bali Pulendran, a Stanford microbiologist and senior author, framed the result as an unusually broad shield against diverse respiratory threats. He also described a practical vision: a seasonal nasal dose that could cover major respiratory viruses while also reducing the risk of bacterial pneumonia and dampening early-spring allergen responses. <\/p>\n\n\n\n The mouse data point toward a tempting outcome: fewer separate shots each year and greater flexibility in readiness if a new respiratory pathogen emerges. Stanford Medicine noted that, if the effect translates to people, the approach could reduce the need for multiple yearly jabs. <\/p>\n\n\n\n But the same reports also draw a bright line between promise and proof. The work still needs human testing to confirm safety, dosing, durability, and the extent to which the effect carries across real-world respiratory viruses and bacteria. Mouse immunity can map onto human immunity in useful ways, but it often diverges in key details. <\/p>\n\n\n\n For now, the study\u2019s central claim stays narrow and testable: in controlled experiments, the universal nasal spray vaccine produced months-long protection in mice against several unrelated respiratory hazards, including viruses, bacteria, and an allergen challenge. That breadth explains why the authors and outside coverage call it one of the closest attempts yet at a truly universal, respiratory-focused vaccine concept. <\/p>\n","protected":false},"excerpt":{"rendered":" Researchers have moved closer to a long-standing goal in immunology: a single formulation that can guard against multiple respiratory threats rather than one pathogen at a time. In mouse experiments, a universal nasal spray vaccine protected against multiple viruses, two hard-to-treat bacteria, and even an allergy trigger linked to asthma-like responses. The team delivered the<\/p>\n","protected":false},"author":6,"featured_media":4539,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,38],"tags":[535,538,533,539,296,540,297,534,537,536],"ppma_author":[43],"class_list":{"0":"post-4537","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"category-science","9":"tag-allergy","10":"tag-covid-19","11":"tag-immunology","12":"tag-influenza","13":"tag-one-health","14":"tag-pneumonia","15":"tag-public-health","16":"tag-respiratory-health","17":"tag-stanford","18":"tag-vaccines"},"yoast_head":"\nMouse Tests Across Viruses, Bacteria, and Allergens<\/h2>\n\n\n\n
What Comes Next, and What the Results Don\u2019t Prove Yet<\/h2>\n\n\n\n